324
Participants
Start Date
February 12, 2025
Primary Completion Date
November 30, 2027
Study Completion Date
December 31, 2027
LP352
LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube.
Site Number - AUS07, Randwick
Site Number - AUS08, Randwick
Site Number - AUS03, Melbourne
Site Number - AUS02, Heidelberg
Site Number - AUS04, Herston
Site Number - AUS05, South Brisbane
Site Number - USA32, New York
Site Number - USA07, Bethesda
Site Number - USA22, Charleston
Site Number - USA09, Atlanta
Site Number - USA02, Gulf Breeze
Site Number - USA05, Orlando
Site Number - USA37, Miami
Site Number - USA11, Tampa
Site Number - USA34, Memphis
Site Number - USA35, Columbus
Site Number - USA39, Cleveland
Site Number - USA14, Cincinnati
Site Number - USA15, Rochester
Site Number - USA38, Chicago
Site Number - USA19, Little Rock
Site Number - USA31, Fort Worth
Site Number - USA25, Houston
Site Number - USA17, Aurora
Site Number - USA26, Los Angeles
Site Number - USA18, Los Angeles
Site Number - USA29, La Jolla
Site Number - USA24, Palo Alto
Site Number - USA28, San Francisco
Site Number - USA33, Portland
Site Number - USA03, Tacoma
Site Number - USA10, Livingston
Site Number - USA36, Morristown
Lead Sponsor
Longboard Pharmaceuticals
INDUSTRY